QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.102376v1 318/2/872    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gustafson, D. L. Articles by Zirrolli, J. A. Search for Related Content PubMed PubMed Citation Articles by Gustafson, D. L. Articles by Zirrolli, J. A.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Tissue Distribution and Metabolism of the Tyrosine Kinase Inhibitor ZD6474 (Zactima) in Tumor-Bearing Nude Mice following Oral Dosing

Department of Pharmaceutical Sciences (D.L.G., E.L.B.-P., A.L.M., J.A.Z.) and the Cancer Center (D.L.G.), University of Colorado Health Sciences Center, Denver, Colorado

ZD6474 [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-quinazolin-4-amine; Zactima] is a tyrosine kinase inhibitor with antiangiogenic and antitumor activity currently undergoing human trials for cancer treatment. Pharmacokinetic studies in animal models are an important component in the clinical development of this agent to relate preclinical studies to patient treatment. In the studies presented here, the pharmacokinetics of ZD6474 was determined in plasma and tissues of MCF-7 tumor-bearing nude mice following single p.o. doses at 10, 25, and 50 mg/kg. Plasma area under the curve and C_max were linear, increasing proportionally with dose. Tissue analysis showed that ZD6474 is extensively distributed to tissues, with liver and lung accumulating concentrations of 212 µg/g (450 µM) and 161 µg/g (340 µM), respectively. Tumor levels ranged from 27 to 71 µg/g at C_max levels across the three dose ranges, and ZD6474 was distributed to all of the tissues in a dose-dependent manner. Analysis of putative ZD6474 metabolites in feces found four, with the N-demethyl-piperidinyl-ZD6474 metabolite being the most prominent but still accounting for less than 2% of the total amount of ZD6474 present. The lack of significant metabolism of ZD6474 is consistent with the relatively long half-life in mice (30 h), as well as that seen in humans (120 h), and the primary method of drug elimination appears to be unchanged in the feces (25%). The incorporation of an empirical approach to dosing in mouse models of cancer in preclinical studies may allow for better prediction of clinical efficacy for ZD6474 alone and in combination with other therapeutic modalities based on equivalent drug exposure.

Address correspondence to: Dr. Daniel L. Gustafson, School of Pharmacy, C-238, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80220. E-mail: daniel.gustafson{at}UCHSC.edu

This article has been cited by other articles:

				E. L. Bradshaw-Pierce, C. A. Steinhauer, D. Raben, and D. L. Gustafson Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma Mol. Cancer Ther., September 1, 2008; 7(9): 3006 - 3017. [Abstract] [Full Text] [PDF]

				W. Ren, B. Korchin, G. Lahat, C. Wei, S. Bolshakov, T. Nguyen, W. Merritt, A. Dicker, A. Lazar, A. Sood, et al. Combined Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor Blockade with Chemotherapy for Treatment of Local, Uterine, and Metastatic Soft Tissue Sarcoma Clin. Cancer Res., September 1, 2008; 14(17): 5466 - 5475. [Abstract] [Full Text] [PDF]

				D. W. Angus, J. A. Baker, R. Mason, and I. J. Martin The Potential Influence of CO2, as an Agent for Euthanasia, on the Pharmacokinetics of Basic Compounds in Rodents Drug Metab. Dispos., February 1, 2008; 36(2): 375 - 379. [Abstract] [Full Text] [PDF]

				T. Troiani, N. J. Serkova, D. L. Gustafson, T. K. Henthorn, O. Lockerbie, A. Merz, M. Long, M. Morrow, F. Ciardiello, and S. G. Eckhardt Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model Clin. Cancer Res., November 1, 2007; 13(21): 6450 - 6458. [Abstract] [Full Text] [PDF]

				V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, F. Persson, G. Stenman, C. Sward, B. Wangberg, M. Stridsberg, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr. Relat. Cancer, June 1, 2007; 14(2): 433 - 444. [Abstract] [Full Text] [PDF]